Aims Low-dose (LD) direct oral anticoagulants (DOACs) in adjunct to antiplatelet therapy,
known as dual-pathway inhibition (DPI), have been tested to prevent ischaemic events in …

Introduction The persistence of elevated rates of ischemic recurrences despite the use of
antiplatelet therapy among patients with atherosclerotic disease together with the …

Atherosclerotic cardiovascular disease (ASCVD), which includes coronary artery disease
(CAD), cerebrovascular disease, and peripheral arterial disease (PAD) is associated with …

Aims To determine the characteristics of patients with coronary artery disease (CAD),
peripheral artery disease (PAD), or both, initiating dual pathway inhibition (DPI) using …

Background: In the COMPASS trial, the combination of acetylsalicylic acid (ASA) plus 2.5 mg
rivaroxaban twice daily (dual-pathway inhibition, DPI) has been shown to be superior to ASA …

Aim Inhibition of thrombin-mediated signaling processes using a vascular dose of
rivaroxaban in adjunct to antiplatelet therapy, known as dual-pathway inhibition (DPI) …

Despite available effective guideline-based preventive therapies, patients with vascular
diseases remain at high-risk of recurrent ischaemic events. Novel therapeutic strategies are …

Aims Dual pathway inhibition (DPI) by adding a vascular dose of rivaroxaban to a single
antiplatelet agent has emerged as a promising antithrombotic strategy. However, in most …

Although acetylsalicylic acid is of proven benefit for secondary prevention in patients with
cardiovascular disease, the risk of recurrent ischemic events remains high. Intensification of …

Introduction In this review, the role of the rivaroxaban-plus-aspirin approach (dual pathway
inhibition–DPI) in patients with chronic coronary syndrome (CCS) and to perform practical …